Combo w/ PD-L1
Advanced Bladder Cancer
Our bladder cancer program brings NK cell therapy into checkpoint maintenance, aiming to strengthen immune response and extend survival for high-risk patients
A powerful combination therapy built for vulnerable patients.
Our NK cells are strategically deployed to do what NO OTHER therapy can.
Combo w/ PD-L1
In Advanced Bladder Cancer
Our bladder cancer program brings NK cell therapy into checkpoint maintenance, aiming to strengthen immune response and extend survival for high-risk patients
Autologous NK Cells Are Superior In This Setting
Unlike exhausted patient NKs or allogeneic NKs requiring lymphodepletion, autologous NKs can truly synergize with avelumab to drive deeper, longer remissions.
Lead Program: Advanced Bladder Cancer
Clinical Setting
Combination with avelumab (anti–PD-L1) in patients who respond to platinum-based chemotherapy.
Therapeutic Mechanism
NK cells enhance checkpoint activity, engaging the endogenous immune system, and sparking a broader immune response.
Differentiation
First NK + PD-L1 combination trial in bladder cancer; well-suited to fragile patient populations
~20,000/yr
Advanced Bladder Cancer in the U.S.
About 7-8,000 of these patients are eligible for PD-L1 maintenance.
<50%
of eligible patients actually receive PD-L1 maintenance
Poor efficacy, potential toxicities, and high cost limits uptake.
Market Impact: Our autologous NK cells can improve clinical uptake of Avelumab increasing: i) number patients on drug, and ii) time on drug – expanding market in two dimensions.
Key Clinical Insights
Efficacy Signals
- MRD deepening in 3 of 4 evaluable patients
- Sustained immune activation markers
- Durable response at 60-month follow-up
- Granzyme B elevation post-infusion
Safety Signals
- No grade 3+ adverse events attributed to treatment
- No cytokine release syndrome
- Well-tolerated across all dose levels
- Favorable pharmacokinetic profile
Other Programs
Multiple Myeloma: post-ASCT Consolidation
Post-autologous stem cell transplant (ASCT) multiple myeloma patients face high relapse rates, with limited safe therapeutic options – our NK cell therapy is intended to boost immune recovery, deepen remissions, and drive cures in this setting.
